CA2171369C - Utilisation d'aggressines d'agents pathogenes permettant d'ameliorer l'administration liposomique d'antibiotiques et (ou) de vaccins - Google Patents

Utilisation d'aggressines d'agents pathogenes permettant d'ameliorer l'administration liposomique d'antibiotiques et (ou) de vaccins Download PDF

Info

Publication number
CA2171369C
CA2171369C CA002171369A CA2171369A CA2171369C CA 2171369 C CA2171369 C CA 2171369C CA 002171369 A CA002171369 A CA 002171369A CA 2171369 A CA2171369 A CA 2171369A CA 2171369 C CA2171369 C CA 2171369C
Authority
CA
Canada
Prior art keywords
liposome
liposomes
antibiotic
lps
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002171369A
Other languages
English (en)
Other versions
CA2171369A1 (fr
Inventor
John W. Cherwonogrodzky
Jonathan P. Wong
Vincent L. Dininno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minister of National Defence of Canada
Original Assignee
Minister of National Defence of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minister of National Defence of Canada filed Critical Minister of National Defence of Canada
Priority to CA002171369A priority Critical patent/CA2171369C/fr
Publication of CA2171369A1 publication Critical patent/CA2171369A1/fr
Priority to US09/251,304 priority patent/US6221386B1/en
Application granted granted Critical
Publication of CA2171369C publication Critical patent/CA2171369C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002171369A 1996-03-08 1996-03-08 Utilisation d'aggressines d'agents pathogenes permettant d'ameliorer l'administration liposomique d'antibiotiques et (ou) de vaccins Expired - Fee Related CA2171369C (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002171369A CA2171369C (fr) 1996-03-08 1996-03-08 Utilisation d'aggressines d'agents pathogenes permettant d'ameliorer l'administration liposomique d'antibiotiques et (ou) de vaccins
US09/251,304 US6221386B1 (en) 1996-03-08 1999-02-17 Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002171369A CA2171369C (fr) 1996-03-08 1996-03-08 Utilisation d'aggressines d'agents pathogenes permettant d'ameliorer l'administration liposomique d'antibiotiques et (ou) de vaccins

Publications (2)

Publication Number Publication Date
CA2171369A1 CA2171369A1 (fr) 1997-09-09
CA2171369C true CA2171369C (fr) 2008-09-09

Family

ID=4157717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002171369A Expired - Fee Related CA2171369C (fr) 1996-03-08 1996-03-08 Utilisation d'aggressines d'agents pathogenes permettant d'ameliorer l'administration liposomique d'antibiotiques et (ou) de vaccins

Country Status (1)

Country Link
CA (1) CA2171369C (fr)

Also Published As

Publication number Publication date
CA2171369A1 (fr) 1997-09-09

Similar Documents

Publication Publication Date Title
Ruyra et al. Targeting and stimulation of the zebrafish (Danio rerio) innate immune system with LPS/dsRNA-loaded nanoliposomes
JP2962555B2 (ja) 溶菌ペプチドによる真核性病原体と新生物の抑制及び繊維芽細胞とリンパ球の刺激
CN102223876A (zh) 纳米乳剂治疗性组合物及其使用方法
UA56132C2 (uk) Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JP2012504150A (ja) 生体活性材料をカプセル化したナノスフェアおよびナノスフェアの製剤化のための方法
DE10003241A1 (de) Verschließen von Bakterienghosts
Knotigová et al. Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity
Nieth et al. A question of attire: dressing up bacteriophage therapy for the battle against antibiotic-resistant intracellular bacteria
EP2661253B1 (fr) Formulation de liposomes pour le traitement ou la prévention de la tuberculose
JP7487892B2 (ja) 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用
Suwanbumrung et al. Oral delivery of a Streptococcus agalactiae vaccine to Nile tilapia (Oreochromis niloticus) using a novel cationic-based nanoemulsion containing bile salts
CN117771348B (zh) 猪髋动脉内皮细胞源性外泌体在制备细菌疫苗中的应用
KR101671376B1 (ko) 돼지 살모넬라 감염 및 prrs 바이러스 예방 또는 치료용 서방형 제제 및 그 제조방법
CA2171369C (fr) Utilisation d'aggressines d'agents pathogenes permettant d'ameliorer l'administration liposomique d'antibiotiques et (ou) de vaccins
EP1259224A2 (fr) Nouvelles formulations cochleaires, procede de preparation et utilisation de celles-ci dans l'administration de molecules biologiquement utiles
WO2001032205A1 (fr) Preventifs muqueux contre la mastite
US20220362400A1 (en) Pivoting electrodynamic composition and medicament
US6221386B1 (en) Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents
JPH02503800A (ja) 炎症過程及びアレルギー性疾患の予防及び治療のための細菌性製剤
Thankappan et al. In vitro and in vivo antimicrobial activity of self-assembled melittin nanoparticles: A comparative study with melittin peptide
JP3649787B2 (ja) 魚類の腸球菌感染症用予防剤およびその用途
KR101978865B1 (ko) Plga로 캡슐화된 불활성화 균체를 포함하는 백신 조성물 및 이의 제조방법
Ali et al. Antibiotics Immobilized Gelatin Nano Carrier Influences on Brucella melitensis Filed Strain
Cherwonogrodzky et al. The Use of Brucella melitensis Smooth-Lipopolysaccharide (sLPS) to Improve Liposomal Formulations for Antibiotic Delivery
RU2111012C1 (ru) Вакцинный препарат для профилактики брюшного тифа

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed